In the ever-evolving field of diabetes management, incretin mimetics have emerged as a transformative therapeutic class. Among these, retaglutide, retatrutide, and trizepatide represent promising additions to the https://laytnwvrx618925.alltdesign.com/the-emerging-landscape-of-glp-1-receptor-agonists-retaglutide-retatrutide-and-trizepatide-57832371